Strati P, Coleman M, Champion R, Ma S, et al. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol 2022 Jul 21. doi: 10.1111/bjh.18368.
PMID: 35861370